SEARCH

SEARCH BY CITATION

References

  • 1
    Bhatnagar AS. The discovery and mechanism of action of letrozole. Breast Cancer Res Treat 2007; 105 (Suppl 1): 717.
  • 2
    Ritter C, Renner AB, Wachtlin J, Bechrakis NE, Krause L. Tamoxifen retinopathy: a case series of clinical and functional data. Ophthalmologe 2008; 105: 544549.
  • 3
    Chung H, Kim D, Ahn SH, Kim JG, Lee JY, Lim JY, Yoon YH. Early detection of tamoxifen-induced maculopathy in patients with low cumulative doses of tamoxifen. Ophthalmic Surg Lasers Imaging 2010; 9: 15.
  • 4
    Zinchuk O, Watanabe M, Hayashi N, Fukushima A, Ueno H. A case of tamoxifen keratopathy. Arch Ophthalmol 2006; 124: 10461048.
  • 5
    Bourla DH, Sarraf D, Schwartz SD. Peripheral retinopathy and maculopathy in high-dose tamoxifen therapy. Am J Ophthalmol 2007; 144: 126128.
  • 6
    Eisner A, Falardeau J, Toomey MD, Vetto JT. Retinal hemorrhages in anastrozole users. Optom Vis Sci 2008; 85: 301308.
  • 7
    Epstein R. Visual impairment in myopic patients with breast cancer receiving adjuvant therapy with aromatase inhibitors. Clin Breast Cancer 2009; 9: 184186.
  • 8
    Karagöz B, Ayata A, Bilgi O, Uzun G, Unal M, Kandemir EG, Ozgün A et al. Hemicentral retinal artery occlusion in a breast cancer patient using anastrozole. Onkologie 2009; 32: 421423.
  • 9
    Eisner A, Thielman EJ, Falardeau J, Vetto JT. Vitreo-retinal traction and anastrozole use. Breast Cancer Res Treat 2009; 117: 916.
  • 10
    Papathanassiou M, Nikita E, Theodossiadis P, Theodossiadis GP, Vergados I. Exemestane-induced corneal epithelial changes. Cutan Ocul Toxicol 2010; 29: 209211.
  • 11
    Coscas G, Cunha-Vaz J, Soubrane G. Macular edema: definition and basic concepts. Dev Ophthalmol 2010; 47: 19.
  • 12
    Elliot SJ, Catanuto P, Espinosa-Heidmann DG, Fernandez P, Hernandez E, Saloupis P, Korach K et al. Estrogen receptor beta protects against in vivo injury in RPE cells. Exp Eye Res 2010; 90: 1016.
  • 13
    Moschos MM, Brouzas D, Apostolopoulos M, Koutsandrea C, Loukianou E, Moschos M. Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal-ERG and OCT study. Multifocal-ERG after use of bevacizumab in ARMD. Doc Ophthalmol 2007; 114: 3744.
  • 14
    Forte R, Cennamo G, Vecchio EC, Tenore R, Aufiero B, de Crecchio G. Bevacizumab in macular edema: functional and anatomic changes in a prospective case series. Retina 2009; 29: 941948.
  • 15
    Bourla DH, Gonzales CR, Mango CW, Moral JN, Wirthlin RS, Schwartz SD. Intravitreous vascular endothelial growth factor (VEGF) inhibitor therapy for tamoxifen induced macular edema. Semin Ophthalmol 2007; 22: 8788.